Journal of Voice
Volume 25, Issue 2 , Pages 236-240 , March 2011

Adverse Effects of Long-Term Proton Pump Inhibitor Use: A Review for the Otolaryngologist

  • D. Brandon Chapman

      Affiliations

    • Department of Otolaryngology, Center for Voice and Swallowing Disorders, Wake Forest University Health Sciences, Winston Salem, North Carolina
    • ,
  • Catherine J. Rees

      Affiliations

    • Department of Otolaryngology, Center for Voice and Swallowing Disorders, Wake Forest University Health Sciences, Winston Salem, North Carolina
    • Corresponding Author InformationAddress correspondence and reprint requests to Catherine J. Rees, Department of Otolaryngology, Center for Voice and Swallowing Disorders, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157.
    • ,
  • Dylan Lippert

      Affiliations

    • Department of Otolaryngology, Center for Voice and Swallowing Disorders, Wake Forest University Health Sciences, Winston Salem, North Carolina
    • ,
  • Robert T. Sataloff

      Affiliations

    • Department of Otolaryngology—Head and Neck Surgery, Drexel University College of Medicine, Philadelphia, Pennsylvania
    • ,
  • S. Carter Wright Jr.

      Affiliations

    • Department of Otolaryngology, Center for Voice and Swallowing Disorders, Wake Forest University Health Sciences, Winston Salem, North Carolina

,Accepted 29 October 2009.

References 

  1. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127:32–35
  2. Koufman JA, Wiener GJ, Wallace CW, Castell DO. Reflux laryngitis and its sequelae: the diagnostic role of ambulatory 24-hour pH monitoring. J Voice. 1988;2:78–89
  3. Koufman JA. Laryngopharyngeal reflux is different from classic gastroesophageal reflux disease. Ear Nose Throat J. 2002;81(Suppl 2):7–9
  4. Mims JW. The impact of extra-esophageal reflux upon disease of the upper respiratory tract. Curr Opin Otolaryngol Head Neck Surg. 2008;16:242–246
  5. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(Suppl 53):1–78
  6. Postma GN, Johnson LF, Koufman JA. Treatment of laryngopharyngeal reflux. Ear Nose Throat J. 2002;81(Suppl 2):24–26
  7. Eslami L, Kalantarian S, Nasseri-Moghaddam S, et al. Long term proton pump inhibitor use and the incidence of gastric (pre) malignant lesions. Cochrane Database Syst Rev. 2008;(2):CD007098
  8. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135–153
  9. Davies M, Wilton LV, Shakir SAW. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11595 patients in England. Drug Saf. 2008;31(4):313–323
  10. Carr CJ, Shangraw RF. Nutritional and pharmaceutical aspects of calcium supplementation. Am Pharm. 1987;NS27:49–57
  11. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–781
  12. Granziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376–1380
  13. Hannan EL, Magaziner J, Wang JJ, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA. 2001;285:2736–2742
  14. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953
  15. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–326
  16. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57:422–428
  17. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148e1–148e5
  18. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–2313
  19. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391–398
  20. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950–955
  21. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960
  22. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128
  23. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–260
  24. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038–1039
  25. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–944
  26. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–718
  27. Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy?. Am J Ther. 2008;15:536–542
  28. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, Jong SDE, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–1348
  29. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med. 1994;121:232–233
  30. FDA Omeprazole Drug Information. Food and Drug Administration website. Available at: www.fda.gov/cder/foi/label/2006/019810s083lbl.pdfAccessed May 16, 2009
  31. Tamim H, Duranceau A, Chen LQ, Lelorier J. Association between use of acid-suppressive drugs and risk of gastric cancer: a nested case-control study. Drug Saf. 2008;31:675–684
  32. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sorensen HT, Olsen JH, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503–1507

PII: S0892-1997(09)00204-5

doi: 10.1016/j.jvoice.2009.10.015

Journal of Voice
Volume 25, Issue 2 , Pages 236-240 , March 2011

Article Tools